Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit

2012 ◽  
Vol 38 (8) ◽  
pp. 981-987 ◽  
Author(s):  
Stéphane Oudard ◽  
Reza-Thierry Elaidi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Sequential Therapy ◽  
Advanced Renal Cell Carcinoma ◽  
Targeted Agents ◽  
Patient Benefit

Targeted Agents for the Treatment of Advanced Renal Cell Carcinoma

2005 ◽  
Vol 6 (7) ◽  
pp. 835-846 ◽  
Author(s):  
M. Staehler ◽  
K. Rohrmann ◽  
N. Haseke ◽  
C. Stief ◽  
M. Siebels
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Targeted Agents

scholarly journals Sequential immune-targeted surgical therapy resulted in disease-free survival in a case with advanced renal cell carcinoma

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kenichi Nishimura ◽  
Noriyoshi Miura ◽  
Naoya Sugihara ◽  
Keisuke Funaki ◽  
Kanae Koyama ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Disease Free Survival ◽  
Sequential Therapy ◽  
Residual Tumor ◽  
Advanced Renal Cell Carcinoma ◽  
Cell Renal Cell Carcinoma ◽  
Disease Free

Abstract Background Currently, immunotherapy is indicated for patients with metastatic RCC or unresectable RCC, but there is no indication for immunotherapy in the neoadjuvant setting. We report a case in which the combined use of nivolumab and ipilimumab and sequential TKI therapy enabled surgical treatment. Case presentation A 71-year-old female was diagnosed with a metastatic clear-cell renal cell carcinoma with a level IV tumor thrombus. She was started on nivolumab-ipilimumab therapy, and was switched to pazopanib monotherapy because the tumor thrombus progressed within the right atrium. The tumor shrank to resectable status with sequential therapy. She then underwent right nephrectomy and thrombectomy. Pathological analysis showed 10–20% residual tumor in the primary tumor, but no viable cells in tumor thrombus. She remains clinically disease-free 1 year after surgery. Conclusion This case suggests the utility of sequential immune-targeted therapy as neoadjuvant therapy in advanced renal cell carcinoma.

Survival Trends among Patients with Advanced Renal Cell Carcinoma in the United States

2014 ◽  
Vol 94 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Binay Kumar Shah ◽  
Krishna Bilas Ghimire
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Survival Rates ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Advanced Renal Cell Carcinoma ◽  
Targeted Agents ◽  
Significant Difference

Introduction: Since the approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). This study was conducted to find out whether the improvements in survival of advanced RCC patients with targeted agents have translated into a survival benefit in a population-based cohort. Methods: We analyzed the SEER 18 (Surveillance, Epidemiology and End Results) registry database to calculate the relative survival rates for advanced RCC patients during 2001-2009, 2001-2005, 2006-2007 and 2008-2009. We also evaluated the survival rates by age (<65 and ≥65 years) and sex. Results: The total number of advanced RCC patients during 2001-2009, 2001-2005, 2006-2007 and 2008-2009 were 7,047, 4,059, 1,548 and 1,440, respectively. During 2001-2009, the 1- and 3-year relative survival rates were 26.7 ± 0.6 and 10.0 ± 0.4%, respectively. There was no significant difference in 1-year relative survival rates for patients diagnosed during 2006-2007 and 2008-2009 compared to those diagnosed during 2001-2005. Similarly, the 3-year survival rates for patients diagnosed during 2006-2007 were similar to those diagnosed during 2001-2005. Conclusions: This population-based study showed that there was no significant improvement in relative survival rates among advanced RCC patients in the era of targeted agents.

Survival trends among patients with advanced renal cell carcinoma (RCC) in the United States.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 422-422 ◽  
Author(s):  
Binay Kumar Shah ◽  
Krishna Bilas Ghimire
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Survival Rates ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Advanced Renal Cell Carcinoma ◽  
P Value ◽  
Targeted Agents

422 Background: Since approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma. This study was conducted to find out whether the improvements in survival of advanced RCC patients with targeted agents have translated into survival benefit in population-based cohort. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) 18 registry database to compare 1- and 3-year relative survival rates among advanced RCC patients during 2001-2009, 2001-2004, and 2006-2009. We also evaluated the survival rates by age (<65 and ≥65 years) and sex. We used SEER*Stat software to analyze the data. Results: The total number of advanced RCC patients during 2001-2009, 2001-2004, and 2006-2009 were 7,055, 3,355 and 2,985 respectively. During 2001-2009, the 1- and 3-year relative survival rates were 26.7± 0.6% and 10.0±0.4% respectively. The 1-year relative survival rates during 2001-2004 and 2006-2009 were 27.0±0.8% and 27.1±0.9%, (p value=1.3) respectively. Similarly, the 3-year survival rates during 2001-2004 and 2006-2009 were 10.1±0.6% and 9.6±0.8%, (p value=1.42), respectively. There was no significant difference in survival rates during 2001-2004 and 2006-2009 periods by age and sex. Conclusions: This population based study showed that there was no significant improvement in relative survival rates among advanced RCC patients in the era of targeted agents. As with other database analyses, limitations of this large study may be incomplete reporting practices and lack of data on treatment.

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

2011 ◽  
Vol 29 (11) ◽  
pp. 977-988 ◽  
Author(s):  
Ateesha F. Mohamed ◽  
A. Brett Hauber ◽  
Maureen P. Neary
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Risk Preferences ◽  
Targeted Agents ◽  
Patient Benefit
Sign in / Sign up

Export Citation Format

Share Document